From Needle to Pill: Oral PCSK9 Inhibition Enters the Lipid-Lowering Armamentarium
Journal of Cardiovascular Pharmacology and Therapeutics · 2026-08 · 31
DOI: 10.1177/10742484261476920 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Cardiovascular Pharmacology and Therapeutics, online erschienen am 04.08.2026. Verfasst von Andrej Belancic und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic and Clinical Pharmacology and Toxicology & Faculty of Medicine, University of Rijeka, Rijeka, Croatia. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Basic and Clinical Pharmacology and Toxicology & Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
- Department of Cardiovascular Diseases, University Hospital of Split (KBC Split), Split, Croatia.
- Department of Pathophysiology, University of Split School of Medicine (MEFST), Split, Croatia.
ORCID-Profile: Andrej Belancic, Josip Andelo Borovac
Zitieren
APA
Belancic, A., & Borovac, J. A. (2026). From Needle to Pill: Oral PCSK9 Inhibition Enters the Lipid-Lowering Armamentarium. Journal of Cardiovascular Pharmacology and Therapeutics, 31. https://doi.org/10.1177/10742484261476920
Vancouver
Belancic A, Borovac JA. From Needle to Pill: Oral PCSK9 Inhibition Enters the Lipid-Lowering Armamentarium. Journal of Cardiovascular Pharmacology and Therapeutics. 2026;31. doi:10.1177/10742484261476920
BibTeX
@article{Belancic2026,
author = {Belancic, Andrej and Borovac, Josip Andelo},
title = {From Needle to Pill: Oral PCSK9 Inhibition Enters the Lipid-Lowering Armamentarium},
journal = {Journal of Cardiovascular Pharmacology and Therapeutics},
year = {2026},
volume = {31},
doi = {10.1177/10742484261476920}
}
EUVIMED